Friday 6-13-2014 Gilead Sciences (GILD) $GILD open

Friday 6-13-2014 Gilead Sciences (GILD) $GILD opened at 80.68 hitting the high price of 81.10 and a day low of 79.87 with a total volume of 7,696,469. GILD had a previous close of 80.58 and has been seeing an average volume of 10,348,250.

Overall Average: 0% Hold

Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!

Shire to Conduct Trials on Vyvanse on FDA's Request - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 5:25PM CDT
Shire plc (SHPG) announced that it has agreed to conduct pediatric clinical studies following FDA's request to investigate the potential use of Vyvanse for the treatment of ADHD in children aged between 4 and 5 years. (full story)

AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 5:20PM CDT
AstraZeneca (AZN) announced that it has entered into an agreement with UK-based Synairgen to in-license its respiratory disease candidate, SNG001. (full story)

Relief for Nektar after AADPAC Voting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 5:10PM CDT
The FDA's AADPAC have recommended that no cardiovascular outcomes study is required for the PAMORA class of drugs, including Nektar's (NKTR) Movantik (full story)

Final Glance: Biotechnology companies
AP - Fri Jun 13, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

Is this Gilead's Biggest Risk?
Cheryl Swanson, The Motley Fool - Motley Fool - Fri Jun 13, 4:00PM CDT
I'll get right to the punch line. Gilead Sciences revolutionary approach to hepatitis C brought in an eye-popping $2.3 billion in its first quarter. If all goes as planned, sales could reach $9 billion by 2017, on target to make Sovaldi one of... (full story)

Sanofi/ Regeneron Present Postive Data on Sarilumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 3:50PM CDT
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) presented positive results from a phase III trial, SARIL-RA-MOBILITY, on pipeline candidate sarilumab. (full story)

J&J, ViiV Healthcare Tie Up for Single-Tablet HIV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 3:20PM CDT
ViiV Healthcare has entered into an agreement with Janssen R&D Ireland Ltd., a subsidiary of Johnson & Johnson. (full story)

Vertex Pharmaceuticals' New Kalydeco Data Out - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 3:10PM CDT
Vertex Pharmaceuticals (VRTX) announced the presentation of data from a phase III study and long-term extension studies on Kalydeco. (full story)

Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors
PR Newswire - Fri Jun 13, 2:30PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors. (full story)

Could This Buyout Go Down As One of the Worst Deals Ever?
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 2:15PM CDT
You certainly don't have to look far these days to see that merger and acquisition activity is picking up across a number of sectors. Investors and Wall Street analysts love to see M&A activity because it signals two things. First, it points to... (full story)

Midday Glance: Biotechnology companies
AP - Fri Jun 13, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.: (full story)

Geron Gains as FDA Lifts Partial Hold on Imetelstat Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 12:10PM CDT
While the lifting of the partial clinical hold is a step in the right direction, the full clinical hold on Geron's (GERN) imetelstat is still in place. (full story)

Bristol-Myers Suffers a Legal Setback - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 10:30AM CDT
The court rejected Bristol-Myers' appeal against a verdict issued in Feb 2013 in a patent related case involving Baraclude. (full story)

Early Glance: Biotechnology companies
AP - Fri Jun 13, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.: (full story)

BIND Therapeutics (BIND) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 8:39AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as its shares rose nearly 7% on the day. (full story)

Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver
PR Newswire - Fri Jun 13, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RL, RAX, GILD, FTNT, and ESRX. (full story)

Sunesis Pharmaceuticals (SNSS) Soars: Stock Adds 8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 7:51AM CDT
Sunesis Pharmaceuticals, Inc. (SNSS) was a big mover last session, as its shares rose roughly 8% on the day. (full story)

Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 7:44AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 9% on the day (full story)

Orexigen Slumps as Obesity Drug Approval Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 5:28PM CDT
Orexigen announced that the FDA has delayed the action date for its obesity candidate, NB32, by three months. (full story)